Patents by Inventor Esohe Ekinaduese Idusogie
Esohe Ekinaduese Idusogie has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 7741072Abstract: A variant of a polypeptide comprising a human IgG Fc region is described, which variant comprises an amino acid substitution at one or more of amino acid positions 270, 322, 326, 327, 329, 331, 333 or 334 of the human IgG Fc region. Such variants display altered effector function. For example, C1q binding and/or complement dependent cytotoxicity (CDC) activity may be altered in the variant polypeptide. The application also discloses a variant of a parent polypeptide comprising a human IgG Fc region, which variant has a better binding affinity for human C1q than the parent polypeptide.Type: GrantFiled: October 12, 2007Date of Patent: June 22, 2010Assignee: Genentech, Inc.Inventors: Esohe Ekinaduese Idusogie, Leonard G. Presta, Michael George Mulkerrin
-
Publication number: 20080138338Abstract: A variant of a polypeptide comprising a human IgG Fc region is described, which variant comprises an amino acid substitution at one or more of amino acid positions 270, 322, 326, 327, 329, 331, 333 or 334 of the human IgG Fc region. Such variants display altered effector function. For example, C1q binding and/or complement dependent cytotoxicity (CDC) activity may be altered in the variant polypeptide. The application also discloses a variant of a parent polypeptide comprising a human IgG Fc region, which variant has a better binding affinity for human C1q than the parent polypeptide.Type: ApplicationFiled: October 12, 2007Publication date: June 12, 2008Applicant: Genentech, Inc.Inventors: ESOHE EKINADUESE IDUSOGIE, Leonard G. Presta, Michael George Mulkerrin
-
Patent number: 7364731Abstract: A variant of a polypeptide comprising a human IgG Fc region is described, which variant comprises an amino acid substitution at one or more of amino acid positions 270, 322, 326,327, 329, 331, 333 or 334 of the human IgG Fc region. Such variants display altered effector function. For example, C1q binding and/or complement dependent cytotoxicity (CDC) activity may be altered in the variant polypeptide. The application also discloses a variant of a parent polypeptide comprising a human IgG Fc region, which variant has a better binding affinity for human C1q than the parent polypeptide.Type: GrantFiled: May 5, 2006Date of Patent: April 29, 2008Assignee: Genentech, Inc.Inventors: Esohe Ekinaduese Idusogie, Leonard G. Presta, Michael George Mulkerrin
-
Patent number: 7297775Abstract: A variant of a polypeptide comprising a human IgG Fc region is described, which variant comprises an amino acid substitution at one or more of amino acid positions 270, 322, 326, 327, 329, 331, 333 or 334 of the human IgG Fc region. Such variants display altered effector function. For example, C1q binding and/or complement dependent cytotoxicity (CDC) activity may be altered in the variant polypeptide. The application also discloses a variant of a parent polypeptide comprising a human IgG Fc region, which variant has a better binding affinity for human C1q than the parent polypeptide.Type: GrantFiled: November 12, 2002Date of Patent: November 20, 2007Assignee: Genentech, Inc.Inventors: Esohe Ekinaduese Idusogie, Leonard G. Presta, Michael George Mulkerrin
-
Publication number: 20030158389Abstract: A variant of a polypeptide comprising a human IgG Fc region is described, which variant comprises an amino acid substitution at one or more of amino acid positions 270, 322, 326, 327, 329, 331, 333 or 334 of the human IgG Fc region. Such variants display altered effector function. For example, C1q binding and/or complement dependent cytotoxicity (CDC) activity may be altered in the variant polypeptide. The application also discloses a variant of a parent polypeptide comprising a human IgG Fc region, which variant has a better binding affinity for human C1q than the parent polypeptide.Type: ApplicationFiled: November 12, 2002Publication date: August 21, 2003Applicant: Genentech, Inc.Inventors: Esohe Ekinaduese Idusogie, Leonard G. Presta, Michael George Mulkerrin
-
Patent number: 6538124Abstract: Isolated nucleic acid, vectors and host cells encoding antibody or immunoadhesin variants, as well as a process for producing the variants. The variants comprise a human IgG Fc region with amino acid substitution(s) therein, and display altered C1q binding function.Type: GrantFiled: October 3, 2000Date of Patent: March 25, 2003Assignee: Genentech, Inc.Inventors: Esohe Ekinaduese Idusogie, Leonard G. Presta, Michael George Mulkerrin
-
Patent number: 6528624Abstract: A variant of a polypeptide comprising a human IgG Fc region is described, which variant comprises an amino acid substitution at one or more of amino acid positions 270, 322, 326, 327, 329, 331, 333 or 334 of the human IgG Fc region. Such variants display altered effector function. For example, C1q binding and/or complement dependent cytotoxicity (CDC) activity may be altered in the variant polypeptide. The application also discloses a variant of a parent polypeptide comprising a human IgG Fc region, which variant has a better binding affinity for human C1q than the parent polypeptide.Type: GrantFiled: March 31, 1999Date of Patent: March 4, 2003Assignee: Genentech, Inc.Inventors: Esohe Ekinaduese Idusogie, Leonard G. Presta, Michael George Mulkerrin
-
Patent number: 6242195Abstract: A variant of a polypeptide comprising a human IgG Fc region is described, which variant comprises an amino acid substitution at amino acid position 329, or at two or all of amino acid positions 329, 331 and 322 of the human IgG Fc region. Such variants display altered effector function. For example, C1q binding and/or complement dependent cytotoxicity (CDC) activity may be reduced or abolished in the variant polypeptide. The application also describes an immune complex and an assay for determining binding of an analyte, such as an Fc region-containing polypeptide, to a receptor.Type: GrantFiled: April 2, 1998Date of Patent: June 5, 2001Assignee: Genentech, Inc.Inventors: Esohe Ekinaduese Idusogie, Michael George Mulkerrin, Leonard G. Presta, Robert Laird Shields
-
Patent number: 6194551Abstract: A variant of a polypeptide comprising a human IgG Fc region is described, which variant comprises an amino acid substitution at amino acid position 329, or at two or all of amino acid positions 329, 331 and 322 of the human IgG Fc region. Such variants display altered effector function. For example, C1q binding and/or complement dependent cytotoxicity (CDC) activity may be reduced or abolished in the variant polypeptide. The application also describes an immune complex and an assay for determining binding of an analyte, such as an Fc region-containing polypeptide, to a receptor.Type: GrantFiled: March 31, 1999Date of Patent: February 27, 2001Assignee: Genentech, Inc.Inventors: Esohe Ekinaduese Idusogie, Leonard G. Presta, Michael George Mulkerrin